GeneNews sets conversion price for convertible debentures

By Susanna Moon

Chicago, Dec. 12 - GeneNews Ltd. said it set the conversion price for its convertible debentures.

Holders may convert the debentures, along with accrued interest, into the company's common shares as of Dec. 18 at a price per share of $0.47, which is 90% of the five-day volume-weighted average price of the common shares on the Toronto Stock Exchange for the period ended on Dec. 11, according to a company press release.

GeneNews is a Toronto-based company focused on developing and commercializing diagnostic tests for the early detection of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.